Advertisement
Research Article

S9, a Novel Anticancer Agent, Exerts Its Anti-Proliferative Activity by Interfering with Both PI3K-Akt-mTOR Signaling and Microtubule Cytoskeleton

  • Chao Zhang equal contributor,

    equal contributor Contributed equally to this work with: Chao Zhang, Na Yang

    Affiliation: Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    X
  • Na Yang equal contributor,

    equal contributor Contributed equally to this work with: Chao Zhang, Na Yang

    Affiliation: Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    X
  • Chun-hao Yang,

    Affiliation: Division of Organic Synthesis, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    X
  • Hua-sheng Ding,

    Affiliation: Division of Organic Synthesis, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    X
  • Cheng Luo,

    Affiliation: Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    X
  • Yu Zhang,

    Affiliation: Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    X
  • Mao-jiang Wu,

    Affiliation: Division of Organic Synthesis, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    X
  • Xiong-wen Zhang,

    Affiliation: Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    X
  • Xu Shen,

    Affiliations: Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China, School of Pharmacy, East China University of Science and Technology, Shanghai, China

    X
  • Hua-liang Jiang,

    Affiliations: Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China, School of Pharmacy, East China University of Science and Technology, Shanghai, China

    X
  • Ling-hua Meng mail,

    lhmeng@mail.shcnc.ac.cn (L-hM); jding@mail.shcnc.ac.cn (JD)

    Affiliation: Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    X
  • Jian Ding mail

    lhmeng@mail.shcnc.ac.cn (L-hM); jding@mail.shcnc.ac.cn (JD)

    Affiliation: Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    X
  • Published: March 18, 2009
  • DOI: 10.1371/journal.pone.0004881

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.